Trial · NCT02545543
Results by group72
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 72
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| The Geometric Mean Titer (GMT) Ratio of Each Virus Strain. | GMT Ratios: GMT Comparator QIV Over GMT Seqirus QIV | A/H1N1 | 1.01 | 95% Confidence Interval 0.93 to 1.09 | Ratio |
| The Geometric Mean Titer (GMT) Ratio of Each Virus Strain. | GMT Ratios: GMT Comparator QIV Over GMT Seqirus QIV | A/H3N2 | 1.05 | 95% Confidence Interval 0.96 to 1.15 | Ratio |
| The Geometric Mean Titer (GMT) Ratio of Each Virus Strain. | GMT Ratios: GMT Comparator QIV Over GMT Seqirus QIV | B/Yamagata | 0.89 | 95% Confidence Interval 0.81 to 0.98 | Ratio |
| The Geometric Mean Titer (GMT) Ratio of Each Virus Strain. | GMT Ratios: GMT Comparator QIV Over GMT Seqirus QIV | B/Victoria | 0.92 | 95% Confidence Interval 0.83 to 1.02 | Ratio |
| The Difference in Seroconversion Rate (SCR) for Each Virus Strain. | SCR Difference = Comparator QIV SCR % Minus Seqirus QIV SCR % | A/H1N1 | -3.1 | 95% Confidence Interval -8.0 to 1.8 | percentage of participants |
| The Difference in Seroconversion Rate (SCR) for Each Virus Strain. | SCR Difference = Comparator QIV SCR % Minus Seqirus QIV SCR % | A/H3N2 | 0.4 | 95% Confidence Interval -4.5 to 5.3 | percentage of participants |
| The Difference in Seroconversion Rate (SCR) for Each Virus Strain. | SCR Difference = Comparator QIV SCR % Minus Seqirus QIV SCR % | B/Yamagata | -3.4 | 95% Confidence Interval -8.3 to 1.5 | percentage of participants |
| The Difference in Seroconversion Rate (SCR) for Each Virus Strain. | SCR Difference = Comparator QIV SCR % Minus Seqirus QIV SCR % | B/Victoria | -2.0 | 95% Confidence Interval -6.9 to 2.9 | percentage of participants |
| Safety Endpoint: The Frequency and Severity of Solicited Local Adverse Reactions. | Seqirus Quadrivalent Influenza Vaccine | Frequency of Solicited Local AEs | 909 | participants | |
| Safety Endpoint: The Frequency and Severity of Solicited Local Adverse Reactions. | Comparator Quadrivalent Influenza Vaccine | Frequency of Solicited Local AEs | 279 | participants | |
| Safety Endpoint: The Frequency and Severity of Solicited Local Adverse Reactions. | Seqirus Quadrivalent Influenza Vaccine | Severe (Grade 3) Solicited Local AEs | 71 | participants | |
| Safety Endpoint: The Frequency and Severity of Solicited Local Adverse Reactions. | Comparator Quadrivalent Influenza Vaccine | Severe (Grade 3) Solicited Local AEs | 21 | participants | |
| Safety Endpoint: The Frequency and Severity of Solicited Systemic Adverse Events (AEs). | Seqirus Quadrivalent Influenza Vaccine | Frequency of Solicited Systemic AEs | 499 | participants | |
| Safety Endpoint: The Frequency and Severity of Solicited Systemic Adverse Events (AEs). | Comparator Quadrivalent Influenza Vaccine | Frequency of Solicited Systemic AEs | 147 | participants | |
| Safety Endpoint: The Frequency and Severity of Solicited Systemic Adverse Events (AEs). | Seqirus Quadrivalent Influenza Vaccine | Severe (Grade 3) Solicited Systemic AEs | 24 | participants | |
| Safety Endpoint: The Frequency and Severity of Solicited Systemic Adverse Events (AEs). | Comparator Quadrivalent Influenza Vaccine | Severe (Grade 3) Solicited Systemic AEs | 6 | participants | |
| Safety Endpoint: The Frequency of Cellulitis-like Reaction. | Seqirus Quadrivalent Influenza Vaccine | 1 | participants | ||
| Safety Endpoint: The Frequency of Cellulitis-like Reaction. | Comparator Quadrivalent Influenza Vaccine | 0 | participants | ||
| Safety Endpoint: The Frequency and Severity of Unsolicited Adverse Events (AEs). | Seqirus Quadrivalent Influenza Vaccine | At least one Unsolicited AE | 269 | participants | |
| Safety Endpoint: The Frequency and Severity of Unsolicited Adverse Events (AEs). | Comparator Quadrivalent Influenza Vaccine | At least one Unsolicited AE | 70 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02545543/results